Transcode Therapeutics Inc (RNAZ)

US · Healthcare · Biotechnology

$1.70-5.56%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-6.7M

EPS

$-7.17

Market cap

$28.8M

Forward P/E

0.0

P/B

2.83

Book value

$-27.38

EPS (TTM)

$-52.06

52-week high

$15.33

52-week low

$1.52

50-day MA

$2.17

200-day MA

$6.45

Beta

1.26

with an average price target of $10.00.

Insiders

1.78%

Institutions

0.44%

Fund	Stake
Yorkville Advisors Global, LP	0.12%
Vanguard Capital Management, LLC	0.04%
Vanguard Fiduciary Trust Co	0.02%
UBS Group AG	0.02%
Mercer Global Advisors Inc.	0.01%
FMR Inc	0.00%
Tower Research Capital LLC	0.00%
Wells Fargo & Co	0.00%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Transcode Therapeutics Inc — free to start.

Data updated 2026-10-19.